[Adverse effects of anti-thymocyte globulin/anti-lymphocyte globulin therapy].
This single-centre study evaluated the adverse effects of anti-thymocyte globulin (ATG) and anti-lymphocyte globulin (ALG) as used for the treatment of aplastic anemia and/or for conditioning regimens prior to stem cell transplantation. ATG/ALG was given to 29 patients a total of 37 times. The incidence of adverse effects was 62.1% (23/37), and fever was the most frequent adverse effect. Therapy was discontinued in only 4 patients (10.8%) due to severe adverse effects. Adverse effects occurred more frequently with ATG (rabbit-derived) than with ALG (horse-derived). Seven patients underwent 2 or 3 cycles of ATG/ALG therapy, for a combined total of 8 times; 6 of those patients (75% (6/8)) experienced adverse effects. Shorter intervals between repeated cycles of therapy appeared to heighten the risk of adverse reactions.
Kobayashi
R
R
Department of Pediatrics, Hokkaido University School of Medicine.
Kaneda
M
M
Watanabe
N
N
Iguchi
A
A
Cho
Y
Y
Yoshida
M
M
Arioka
H
H
Naito
H
H
Shikano
T
T
Ishikawa
Y
Y
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology*; D019172:Transplantation Conditioning
D000961:Antilymphocyte Serum